A family history of breast cancer can raise a woman's risk, but it does not always mean cancer is inherited. This guide explains hereditary breast cancer, BRCA1, BRCA2 and PALB2, who should consider testing, what results mean and how families can manage risk. Related: prevention, screening, young women, men, treatment in India.

Does Breast Cancer Run in Families?
Yes, it can — but not every family with several cases has an inherited syndrome.
- **Familial breast cancer** — several relatives affected without an identified pathogenic variant; shared lifestyle, reproductive, environmental and polygenic factors may contribute.
- **Hereditary breast cancer** — an inherited pathogenic variant raises risk and can pass from parent to child.
About 5–10% of breast cancers are commonly estimated to be hereditary (estimates vary). Most breast cancers are not explained by one inherited cancer-causing gene. Having one relative with breast cancer does not mean you will develop it. Risk depends on which relative, age at diagnosis, number affected, bilateral disease, ovarian/pancreatic/prostate cancers, known variants and your own history.
How Much Does Family History Increase Risk?
The increase is not the same for everyone. Concern rises with multiple close relatives, young-onset disease, several generations, breast plus ovarian cancer, male breast cancer or a known pathogenic variant.
- **First-degree:** mother, sister, daughter.
- **Second-degree:** grandmother, aunt, half-sister, granddaughter, niece — especially when several are on the same side.
Younger age at diagnosis can be a stronger hereditary clue than late-life disease, but age alone does not decide testing.
Hereditary Breast and Ovarian Cancer Syndrome
HBOC is mainly linked to pathogenic BRCA1/BRCA2 variants. These genes help repair DNA. Harmful inherited variants can raise risks of breast, ovarian, fallopian tube, primary peritoneal, pancreatic and prostate cancers (especially BRCA2 in men), and male breast cancer. Risks differ by gene and variant. Not every carrier develops cancer.
Which Genes Matter?

| Gene | Associated condition or risk | Why it matters |
|---|---|---|
| BRCA1 | HBOC | Increased breast and ovarian cancer risk |
| BRCA2 | HBOC | Breast, ovarian, pancreatic, prostate, male breast risk |
| PALB2 | Hereditary susceptibility | Important breast cancer gene |
| TP53 | Li-Fraumeni | Several cancers including young-onset breast cancer |
| PTEN | PTEN hamartoma syndrome | Breast, thyroid, endometrial and other risks |
| CDH1 | HDGC | Diffuse gastric and lobular breast cancer |
| CHEK2 / ATM / BARD1 | Moderate penetrance | Selected variants raise breast cancer risk |
Panel choice should follow personal/family history — a larger panel is not automatically better.
BRCA1 vs BRCA2
- **BRCA1** — female breast and ovarian risk; BRCA1-related cancers more often triple-negative (not always).
- **BRCA2** — female and male breast, ovarian, pancreatic and prostate risk.
A pathogenic BRCA variant increases risk but does not guarantee cancer.
How Genes Are Inherited
BRCA1/BRCA2 pathogenic variants usually follow autosomal dominant inheritance: one altered copy confers susceptibility. Each child of a carrier has a ~50% chance of inheriting it. Variants can come from either parent — fathers can pass them without having breast cancer themselves. Male breast cancer in a family is an important clue. See also breast cancer in men.
Family Patterns That Suggest Hereditary Risk
- Young-onset breast cancer
- Ovarian cancer in a close relative
- Male breast cancer
- Multiple relatives with breast cancer
- Bilateral or multiple primary breast cancers
- Breast + ovarian/pancreatic/selected prostate cancers
- Known pathogenic variant
- Triple-negative breast cancer, especially younger
Who Should Consider Genetic Testing?
Not every woman needs testing. It is considered when history suggests higher likelihood of an inherited variant — including younger-onset breast cancer (ASCO–SSO recommends offering BRCA1/2 testing to newly diagnosed patients ≤65, with criteria for selected older patients), strong family history, ovarian cancer, bilateral/multiple primaries, selected triple-negative cases, known family variants and men with breast cancer.
What Is Germline Genetic Testing?
Testing examines inherited DNA (usually blood or saliva), not the same as mammography, ultrasound or tumour biopsy. Results may be pathogenic, likely pathogenic, benign, likely benign or variants of uncertain significance (VUS). Interpretation needs a qualified professional.
| Feature | Tumour genetic testing | Germline genetic testing |
|---|---|---|
| Sample | Cancer tissue | Usually blood or saliva |
| Purpose | Tumour changes | Inherited variants |
| Family implications | Usually not direct | May affect blood relatives |
Genetic Counselling

Before testing: personal/family history, pedigree, outcomes, limitations, implications, consent. After: risk, screening, risk-reducing options, treatment implications, relative testing and psychosocial issues.
What Results Mean
- **Pathogenic / likely pathogenic** — inherited risk increase; not a cancer diagnosis.
- **True negative** — known family variant specifically absent.
- **Uninformative negative** — no prior family variant; residual familial risk may remain.
- **VUS** — not a confirmed mutation; ASCO–SSO: do not use VUS alone for management.
- **Benign / likely benign** — generally no management change from that finding.
If BRCA1/BRCA2 Is Positive

- Intensified screening (clinical exam, MRI, mammography as indicated)
- Risk-reducing mastectomy (personal decision; residual risk remains)
- Risk-reducing salpingo-oophorectomy timing by gene/age/fertility plans
- Selected preventive endocrine medicines for some women
BRCA status can also influence surgery choices and PARP inhibitor eligibility (e.g. olaparib/talazoparib in selected settings). Oncologists decide suitability.
Testing and Cost in India
BRCA and multigene panels are available through selected Indian labs and cancer centres. Choose by quality, genes covered, variant detection methods, counselling and interpretation — not price or gene count alone. ISMPO 2025 hereditary breast/ovarian consensus discusses counselling and tele-genetic options. Costs vary; request a written estimate covering counselling.
| Named pathway | GAF planning range in India | Notes |
|---|---|---|
| Precision oncology | $2,000–$7,000 | Selected genetic / biomarker pathways |
| Lumpectomy | $3,000–$7,500 | Breast-conserving surgery when suitable |
| Mastectomy | $4,500–$10,000 | Selected surgical pathways |
| Chemotherapy | $1,500–$8,000+ | When systemic therapy is indicated |
| Hormone therapy | $1,000–$4,500 | Hormone receptor-positive settings |
GAF pathway ranges support planning after high-risk assessment or diagnosis — not a fixed genetic-test price list. See the breast cancer cost guide.
Cascade Testing and Negative Strong-Family History
If a relative has a confirmed pathogenic BRCA variant, adult blood relatives may be offered targeted testing. Predictive BRCA testing is generally not for children under 18. A negative broad test with a strong family history may still justify enhanced screening — an uninformative negative does not erase familial risk.
Risk Management and Preparing for Counselling
- Personalised screening
- Risk-reducing medicines when appropriate
- Risk-reducing surgery for selected high-risk variants
- Healthy weight, activity, limited alcohol
- Symptom awareness
| Information | Details to collect |
|---|---|
| Relative affected | Mother, sister, daughter, aunt, grandmother |
| Type of cancer | Breast, ovarian, pancreatic, prostate |
| Age at diagnosis | Approximate age |
| Side of family | Mother's or father's side |
| Genetic test history | Prior reports if available |
International Patients
Share biopsy/IHC, imaging, treatment records and family/genetic reports before travel. GAF can coordinate hospital arrangements; specialists make clinical decisions. International patients. Specialists: medical oncology, surgical oncology.
Frequently Asked Questions
Does breast cancer always run in families?
No. Most breast cancers are not caused by a known inherited pathogenic variant. Family history can still increase risk and may indicate genetic assessment.
If my mother had breast cancer, will I also get it?
Not necessarily. An affected mother can increase risk, but it does not mean cancer is inevitable.
At what age should a woman with a family history start screening?
There is no single age. It depends on relatives’ ages at diagnosis, number affected, genetic results and overall risk.
What is the difference between BRCA1 and BRCA2?
Both repair DNA. Pathogenic variants raise breast cancer risk. BRCA1 is more often linked with triple-negative disease; BRCA2 is especially relevant to male breast and prostate cancer risk.
Can a father pass a breast cancer gene to his daughter?
Yes. BRCA1/BRCA2 variants can come from either parent.
Can men carry BRCA mutations?
Yes. Men can inherit and pass BRCA variants and may have higher risks of male breast, prostate and pancreatic cancers.
Does a positive BRCA test mean I will develop breast cancer?
No. It means increased inherited risk, not certainty.
What does a negative BRCA test mean?
No pathogenic variant was found in the genes examined. A true negative for a known family variant differs from an uninformative negative.
What is a VUS in genetic testing?
A variant of uncertain significance. It should not be treated as a confirmed cancer-causing mutation or used alone for preventive surgery decisions.
Is BRCA testing available in India?
Yes, through selected laboratories and cancer centres. Confirm quality, panel coverage and counselling access.
Can a woman with a BRCA mutation have children?
Yes. Discuss reproductive planning and the 50% inheritance chance with specialists.
Can breast cancer be prevented in BRCA carriers?
Risk cannot be eliminated, but enhanced screening, medicines and selected surgeries can reduce risk or aid earlier detection.
Should every woman with breast cancer undergo genetic testing?
Not every woman needs the same test. ASCO–SSO guidance recommends offering BRCA1/2 testing to newly diagnosed patients ≤65, with selected older patients based on criteria.
If my genetic test is negative, can I stop screening?
No. Continue screening based on personal risk and guidelines.
Does genetic testing help choose treatment?
Yes in selected cases — surgery choices, risk-reducing measures and PARP inhibitor eligibility.
What is cascade testing?
Testing blood relatives for a known family pathogenic variant after counselling.
Conclusion
Family history is important but incomplete. Some families carry BRCA1/BRCA2/PALB2 variants; others have several cases without an identified gene. Genetic counselling helps separate these situations and guide screening, testing and prevention.
Family history should lead to informed assessment, not fear.
Medical Sources and References
Medical disclaimer: Educational only. Genetic testing should be selected and interpreted by qualified professionals.